Evaxion to Present Three-Year EVX-01 Data at ESMO 2026; Two-Year Results Show 75% ORR
EVAX sits 27% above its 52-week low of $2.45.
Summary
Evaxion announced it will present three-year efficacy data for its personalized cancer vaccine EVX-01 at ESMO 2026. The two-year data showed a 75% response rate and durable responses in advanced melanoma.
Key Events · Product Development and Regulatory · EVAX
-
ESMO 2026 Presentation
Three-year clinical efficacy data for personalized cancer vaccine EVX-01 will be presented at the ESMO Congress on October 24, 2026.
-
Two-Year Efficacy Data
Previously reported two-year data showed a 75% objective response rate (12/16 patients), 92% durable response rate, and 54% deepened response rate in advanced melanoma.
-
Stand-Alone Therapy Data
Third-year data will include results from patients receiving EVX-01 as stand-alone therapy, potentially demonstrating vaccine effect without anti-PD-1 combination.
-
Partnership Catalyst
Presentation at a major oncology conference provides an opportunity to discuss data with potential business partners amid emerging pivotal data in the personalized cancer vaccine field.
Analysis · EVAX · Life Sciences
A major oncology conference sets the stage for Evaxion to unveil three-year clinical efficacy data from its lead personalized cancer vaccine, EVX-01, at the ESMO Congress in October 2026. The two-year snapshot already delivered a 75% objective response rate and durable responses in advanced melanoma. With the upcoming readout including stand-alone therapy results, the case for EVX-01 as a differentiated asset could strengthen considerably. For a company with a $26M market cap, positive data at this venue can serve as a powerful catalyst for partnership discussions and investor sentiment.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26M. The 52-week trading range was $2.45 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.